Apex Technology Acquisition Corp. (APXT) Shareholders Approve AvePoint Deal
by Nicholas Alan Clayton on 2021-07-01 at 7:36am

Apex Technology Acquisition Corp.  (NYSE:APXT) announced in an 8-K filing its shareholders approved its combination with data management software company AvePoint.

Importantly, just 17,372 shares were redeemed in connection with the vote, removing an insignificant amount from its trust. This makes sense as Apex traded above $12 throughout June 28, the day of its redemption deadline and closed Wednesday at $12.25.

Apex also dangled a somewhat odd incentive to shareholders to vote early, offering to donate $1 to non-profit Girls Who Code for each shareholder that voted by June 30 to a maximum of $100,000. A donation of that size seems rather doable for the team given the sums involved in the transaction, and many SPACs have set aside a portion of their promote shares to charity without conditions. In the end, 61% of shares participated in the vote whether for charitable purposes or not.

The parties initially announced the $1.7 billion deal on November 23. AvePoint provides data migration as well as document protection and recovery software that integrates with Microsoft 365 software for users ranging from small enterprises to the US State Department.

The deal was the third oldest SPAC transaction in the announced-but-not-yet-complete column behind Stable Road (NASDAQ:SRAC)’s combination with Momentus that hit regulatory speed bumps and Alberton (NASDSAQ:ALAC)’s tie-up with SolarMax, both of which were announced in October 2020.

For a full list of measures on Apex’s ballot as well as vote tallies click HERE.


ADVISORS

  • Evercore Group L.L.C. (“Evercore”) is acting as financial advisor to AvePoint.
  • Citigroup Global Markets Inc. (“Citi”), Goldman Sachs & Co. LLC (“Goldman Sachs”), Evercore and Cowen Inc. are acting as capital markets advisors to AvePoint.
  • William Blair & Company is acting as a financial advisor to Apex.
  • Cantor Fitzgerald, L.P. is acting as a capital market advisor to Apex.
  • Goldman Sachs, Citi and Evercore are acting as private placement agents to Apex.
  • Cooley LLP is acting as legal counsel to AvePoint.
  • Latham & Watkins LLP is acting as legal counsel to Apex.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved